только для медицинских специалистов

Консультант врача

Электронная медицинская библиотека

Раздел 3 / 6
Страница 7 / 18

Список сокращений

Внимание! Часть функций, например, копирование текста к себе в конспект, озвучивание и т.д. могут быть доступны только в режиме постраничного просмотра.Режим постраничного просмотра
 
 
 
 
 

Выводы

С целью иммунокоррекции сепсиса обоснованным является применение пентаглобина в дозе 5 мл/кг массы те- ла, вводимого со скоростью 28 мл/ч в течение трех дней подряд (категория доказательности А).

  • В настоящее время нет доказательств эффективности других иммунокорригирующих препаратов, и поэтому их использование не должно осуществляться в рутинной практике.
  • Научные исследования, посвященные иммунокоррекции сепсиса, многочисленны и далеки от завершения.
  • Рассматривая вопрос об иммунокоррекции сепсиса, необходимо придерживаться вышеизложенных критериев, которым должен соответствовать назначаемый препарат.

Список литературы

  1. Abraham E., Anzueto A., Gutierrez G., et al. Double-blind rando- mized controlled trial of monoclonal antibody human tumor necrosis factor in treatment of septic shock. Lancet 1998; 351: 929—933.
  2. Abraham E., Glauser M.P., Butler T., et al. p55 tumor necrosis fac- tor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled mulcenter trial. JAMA 1997; 277: 1531—1538.
  3. Albertson T.E., Panacek E.A., MacArthur R.D., et al. Multicenter evaluation оf a human monoclonal antibody to Enterobacteriaceae common antigen in patients with Gram-negative sepsis. Crit. Care Med. 2003; 31: 419—427.
  4. Alejandria M.M., Lansang M.A., Dans L.F., Mantaring J.B.V. Intravenous immunoglobulin for treating sepsis and septic shock (Cochrane review). The Cochrane Library 2002; issue 4. Oxford: Update Software.
  5. Annane D., Sebille V., Charpentier C., et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patientswith septic shock. JAMA 2002; 288: 862—871.
  6. Arndt P., Abraham E. Immunological therapy of sepsis: experi- mental therapies. Int. Care Med. 2001; 27: 104—115.
  7. Arons M.M., Wheeler A.P., Bernard G.R., et al. Effects of ibuprofen on the physiology and survival of hypothermic sepsis. Crit. Care Med. 1999; 27: 699—707.
  8. Bernard G.R., Wheeler A.P., Russell J.A., et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. N Eng J Med. 1997; 336: 912—918.
  9. Bochud P.Y., Calandra T. Pathogenesis of sepsis: new concepts and implications for future treatment. BMJ 2003; 326: 262—266.
  10. Bone R.C., Balk R.A., Fein A.M., et al. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. Crit. Care Med. 1995; 23: 994—1006.
  11. Carle J. Immunological therapy in sepsis: currently available. Int. Care Med. 2001; 27: 93—103.
  12. Carvalho P.R.A., Trotta E.A. Advances in sepsis diagnosis and treatment. J de Pediatria 2003; 79 (2): 195—204.
  13. Cronin L., Cook D.J., Carlet J. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit. Care Med. 1995; 23: 1430—1439.
  14. Dhainaut J.F.A., Tenaillon A., Hemmler M., et al. Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit. Care Med. 1998; 26: 1963—1971.
  15. Fagan E.A., Singer M. Immunoterapy in the management of sep- sis. Posgrad Med. 1995; 71: 71—78.
  16. Friedrich I., Silber R.E., Bauman B., et al. IgM-enriched immunoglobulin preparation for immunoprophylaxis in cardiac surgery. Eur J Med. Res. 2002 dec 17; 7 (12): 544—549.
  17. Fujiwara T., et al. Effect of immunoglobulin therapy on polymor- phonuclear leucocytes in whole blood of neonates. Clin. Exp. Immunol. 1997; 107: 435—439.
  18. Glauser M.P. Pathophysiology basis of sepsis: considerations for future strategies of intervention. Crit. Care Med. 2000; 28: 4—8.
  19. Haque K.N., et al. Comparsion of two types of intravenous immunoglobulins in the treatment of neonatal sepsis. Clin. Exp. Immunol. 1995; 101: 328—333.
  20. Hoffmann J.N., Vollmar B., Laschke M.W., et al. Adverse effect of heparin on antithrombin action during endotoxemia: microhemody- namic and cellular mechanisms. Thromb Hemost 2002; 88: 242—252.
  21. Hotchkiss R.S., Karl I.E. The pathophysiology and treatment of sepsis. N Eng J Med. 2003; 348: 138—150.
  22. Keh D., Boehnke T., Weber-Cartens S., et al. Immunologic and hemodynamic effects of rlow dose hyrdrocortisone in septic shock. Am J Resp. Crit. Care Med. 2003; 167: 512—520.
  23. Lauterbach R., Pawlik D., Kowalczyk D., et al. Effect of the immunomodulating agent, pentoxifylline, in the treatment of sep- sis in prematurely delivered infants: a placebo-controlled, double- blind trial. Crit. Care Med. 1999; 27: 807—814.
  24. Melero J., et al. Human polyreactive IgM monoclonal antibodies with bloking activity against self-reactive IgG. Scand J Immunol. 1997; 45: 393—400.
  25. Messori A., Vacca F., Vaiani M., Tripolli S. Antitrombin III in patients admitted to intensive care units: a multicentre observa- tional study. Crit. Care Med. 2002; 6: 447—451.
  26. Mohr M., et al. Effect of early treatment with immunoglobulin on critical illness polyneuropathy following MOF and gram-negative sepsis. Int. Care Med. 1997; 23: 1144—1149.
  27. Opal S.M., Fisher C.J., Dhainaut J.F.A., et al. Confirmatory inter- leukin-1 receptor antagonist trial in severe sepsis: a phase HI, ran- domized, double-blind, placebo-controlled, multicenter trial. Crit. Care Med. 1997; 25: 1115—1124.
  28. Poynton C.H., et al. Use of IgM-enriched intravenous immunoglo- bulin (Pentaglobin) in bone marrow transplantation. Bone Marrow Transpl. 1992; 9: 451—457.
  29. Rinaldi M., et al. Effectiveness of immunoglobulins for the pre- vention of systemic infections. Clin. Drug Invest. 1995; 10: 328—336.
  30. Rivers E., Nguyen B., Havstad S., et al. Early goal-directed thera- py in the treatment of severe sepsis and septic shock. N Eng J Med. 2001; 345: 1368—1377.
  31. Roemisch J., Gray E., Hoffmann J.N., Wiedermann C.J. Antitrombin: a new look at the actions of a serine protease inhibitor. Blood Coagul. Fibrinolisis 2002; 13: 657—670.
  32. Rott R.K., Lodato R.F., Patrick W., et al. Pneumonia Sepsis Study Group Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis. Crit. Care Med. 2003; 31: 367—373.
  33. Saez-Llorens X., McCracen G.H. Sepsis syndrome and septic shock in pediatrics: current concepts of terminology, pathophysiology, and management. J Pediatr 1993; 123: 497—508.
  34. The ARDS network. Ketokonazole for early treatment of acute lung injury and acute respiratory distress syndrome: a rando- mized controlled trial. JAMA 2000; 283: 1995—2002.
  35. Tugrul S., Ozcan R.E., Akinci O., et al. The effects of IgM-enriched immunoglobulin preparation in pacients with severe sepsis. Crit. Care 2002; 6: 357—362.
  36. Vincent J.L., Abraham E., Annane D., et al. Van den Berghe G. Reducing mortality in sepsis: new directions. Crit. Care 2002; 6 (3): 1—18.
  37. Warren B.L., Eid A., Singer R., et al. Caring for the critically ill patient. High-dose antitrombin III in severe sepsis: a randomized controled trial. JAMA 2001; 286: 1869—1878.
  38. Wolf H.M., Eibl M.M. Immunomodulatory effect of immunoglo- bulins. Clin. Exp. Rheumatol. 1996; 14 (15): 17—25.
  39. Zeni F., Freeman B., Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock: a reassesment. Crit. Care Med. 1997; 25: 1095—1100.